Research Publications

Back

Tumour morphology predicts PALB2 germline mutation status


Teo, ZL; Provenzano, E; Dite, GS; Park, DJ; Apicella, C; Sawyer, SD; James, PA; Mitchell, G; Trainer, AH; Lindeman, GJ; Shackleton, K; Cicciarelli, L; Buys, SS; Andrulis, IL; Mulligan, AM; Glendon, G; John, EM; Terry, MB; Daly, M; Odefrey, FA; Nguyen-Dumont, T; Giles, GG; Dowty, JG; Winship, I; Goldgar, DE; Hopper, JL; Southey, MC
2013-07-09
BRITISH JOURNAL OF CANCER
Journal Article
109
1
154-163
Background: Population-based studies of breast cancer have estimated that at least some PALB2 mutations are associated with high breast cancer risk. For women carrying PALB2 mutations, knowing their carrier status could be useful in directing them towards effective cancer risk management and therapeutic strategies. We sought to determine whether morphological features of breast tumours can predict PALB2 germline mutation status. Methods: Systematic pathology review was conducted on breast tumours from 28 female carriers of PALB2 mutations (non-carriers of other known high-risk mutations, recruited through various resources with varying ascertainment) and on breast tumours from a population-based sample of 828 Australian women diagnosed before the age of 60 years (which included 40 BRCA1 and 18 BRCA2 mutation carriers). Tumour morphological features of the 28 PALB2 mutation carriers were compared with those of 770 women without high-risk mutations. Results: Tumours arising in PALB2 mutation carriers were associated with minimal sclerosis (odds ratio (OR)=19.7; 95% confidence interval (CI)=6.0-64.6; P=5 x 10(-7)). Minimal sclerosis was also a feature that distinguished PALB2 mutation carriers from BRCA1 (P=0.05) and BRCA2 (P=0.04) mutation carriers. Conclusion: This study identified minimal sclerosis to be a predictor of germline PALB2 mutation status. Morphological review can therefore facilitate the identification of women most likely to carry mutations in PALB2.
NATURE PUBLISHING GROUP
PALB2; hereditary; breast cancer; tumour morphology
Stem Cells and Cancer
10.1038/bjc.2013.295
rom twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Back
Creation Date 2013-07-09 12:00:00